On May 12th, the biaseparations.com website will be retired and migrated tosartorius.com.Learn moreabout our combined offering today!

New CIM Monolith QA HR Line

Monolithic CIM QA HR (High Reproducibility) columns for the highest batch-to-batch and scale-to-scale reproducibility in chromatography ever

CIM monolith QA HR line is a new generation of pre-packed chromatographic monolithic products developed to meet the most demanding separation and purification needs. HR stands for High Reproducibility between batches and different scales. 

CIM QA HR line includes all standard CIM column scales: CIMmultus for preparative applications, from 1 mL to 8 L, as well as CIM QA HR 96-well plates, analytical CIMac QA HR columns and industrial 40L CIMmultus QA HR columns. In combination with the novel QA methods, outstanding separation of different AAV capsids for enrichment of full AAV capsid should be possible at any scale.

Watch the webinar to learn more on the new High Reproducibilty Line
Watch the webinar On-Demand

CIMmultus QA HR Columns

CIM monolith QA HR provides reproducible purity allowing for enrichment of any full AAV capsids and its chimeras, or surface modified capsids, regardless of the batch or size of the column used.  

The new CIM QA HR line features the same quaternary amine (QA) ligand as the standard CIM QA columns, but implements an additional specialized testing procedure with strict release criteria. Acceptance criteria of the CIM QA HR are based on the conductivity values of the empty AAV capsids elution, instead of the ion capacity test using small ionic molecules applied for the standard CIM QA.

As the production methods are the same, the quality assurance regulatory support file for the QA HR cGMP columns is also the same as for the standard QA cGMP product line. This allows users of CIMmultus QA cGMP compliant columns a smooth transition from the standard CIMmultus QA line to the new CIMmultus QA HR line.  

CIM QA HR scale-to-scale reproducibility (Figure 1):
Scale-to-Scale Reproducibility of the CIM QA HR Line
Figure 1: Iso-conductivity overlay of AAV2/8 empty-full separation in ascending KCl gradient on CIMmultus QA HR 1 mL, 4 mL, 8 mL columns and Specimen units of CIMmultus QA HR 80 mL, 800 mL and 8000 mL column. Specimen is a small volume device that can be primarly used as control to follow material lot-to-lot variability of purchased columns. Empty capsids eluted at an average KCl concentration of 92.4 mM with a 0.4% RSD. 

Novel QA High Resolution Method to Separate Different AAV Capsids

The presence of partial and heavy AAV capsids in AAV gene therapy products is an increasing concern due the potential carryover of host cell DNA (hcDNA) and plasmid DNA (pDNA) fragments.  

By using recently developed separation methods in combination with CIMmultus QA HR columns, it should be possible to remove one log of partial and heavy capsids and about two orders of magnitude of the empty AAV capsid without sacrificing much of the product at any scale. 

Figure 2 shows a difference between the standard and new QA methods. The two methods were carried out using the same strong anion exchange CIMac QA analytical column applying the same CIMmultus SO3 pre-purified sample. The novel QA method provides significantly improved resolution between full capsids and other non-active, potentially unsafe capsids.   

The chromatograms show elution profiles of both methods monitored by three different detectors, UV (at 260 nm and 280 nm), Trp Fluorescence and Light Scattering.  

Elution profiles of standard method and novel QA method.
Figure 2: Elution profiles of standard method and novel QA method. 

Watch the webinar
Watch the video

Take a look at our method guide.

*The new QA method is patent pending but already available as part of Cornerstone® Biomanufacturing Services.

Cornerstone® Biomanufacturing Services.

This service typically consists of 2 steps:

Step 1: Feasibility StudyFirst, the Feasibility study is performed to demonstrate that the method provides the expected high resolution separation using client’s AAV sample. Outcome of this study is a proof of principle and consists only of chromatograms and a basic interpretation of the characteristics of the sample based on the chromatograms.
Step 2: Full StudyAfter the feasibility study, one can proceed with the paid full study using the novel empty-full AAV method, and the client receives a worldwide nonexclusive, free of charge license for using novel QA empty-full method.